PairX Bio
Singapore, Singapore· Est.
Variant‑specific biologics that deliver tumor‑selective immunotherapy for broader oncology impact.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Variant‑specific biologics that deliver tumor‑selective immunotherapy for broader oncology impact.
OncologyImmunology
Technology Platform
Variant‑selective biologics that target tumor‑specific cell‑surface protein variants, enabling multiple therapeutic formats (TCEs, ADCs, radioligands, bispecifics) for high tumor specificity.
Opportunities
Broad patient coverage through prevalent tumor variants and a flexible multimodal platform could unlock sizable oncology markets and attract partnership deals.
Risk Factors
Preclinical stage with no clinical data, high R&D costs, and competition from other precision‑oncology platforms pose significant execution risks.
Competitive Landscape
Differentiates from traditional antigen‑targeting biologics by offering variant‑level selectivity, but competes with emerging bispecific, ADC, and T‑cell engager developers.